Nanobac Life Sciences Announces Upcoming Presentation at the 2005 PDA Viral and TSE Safety Conference
-- Olavi Kajander, MD, PhD, University of Kuopio, will present a poster on "Self-replicating Calcium-Phosphate Macromolecular Complexes: Contamination Control in Biopharmaceuticals" on Wednesday, May 18, 2005.
“Self-replicating Calcium-Phosphate Macromolecular Complexes: Contamination Control in Biopharmaceuticals”
The PDA Viral and TSE Safety Conference, co-sponsored by both EMEA and FDA, provides an opportunity for dialog on current guidance, critical issues and new technology and approaches to viral and TSE safety. The conference brings together representatives from both EMEA and FDA with biopharmaceutical manufacturers, manufacturers of enabling technologies and contract testing organizations.
About Nanobac Life Sciences
Nanobac Life Sciences, Inc. is dedicated to improving people's health through the detection and eradication of calcifying nano-sized bacteria-like particles "Nanobacteria". The Company's pioneering research is establishing the pathogenic role of Nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease.
Nanobac has identified and established two biomarkers of nanobacterial infection, and expects to file for FDA approval of its NB2(TM) ELISA assays to detect nanobacterial antigen and IgG antibody. It is also leveraging its proprietary knowledge and intellectual property to develop novel therapeutics to treat nanobacterial infections. The Company currently markets a patented nanobiotic regimen and has developed tests to detect Nanobacteria in blood, serum, tissues, urine and spinal fluids. Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our websites at: http://www.nanobaclifesciences.com or http://www.nanobacsciences.com.
Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.